Literature DB >> 7355367

The mesocaval C shunt.

J L Cameron, D P Harrington, W C Maddrey.   

Abstract

A modification of the mesocaval interposition H shunt utilizes the anterior cephalad portion of the superior mesenteric vein on top of the uncinate process of the pancreas as the site of anastomosis. This site is above the branches of the superior mesenteric vein and ensures a vein of large caliber. When the graft is anastomosed to this portion of the vein, it assumes a C configuration.

Mesh：

Year:  1980        PMID： 7355367

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN： 0039-6087


  7 in total

1.  The mesocaval 'C' shunt: improved surgical management for the Budd Chiari syndrome.

Authors:  J P McCabe; R Waldron; D O'Brien; D F Courtney
Journal:  Ir J Med Sci       Date:  1989-08       Impact factor: 1.568

2.  The Budd-Chiari syndrome. Treatment by mesenteric-systemic venous shunts.

Authors:  J L Cameron; H F Herlong; H Sanfey; J Boitnott; S L Kaufman; V L Gott; W C Maddrey
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

3.  Surgical management of patients with the Budd-Chiari syndrome.

Authors:  H Sanfey; J K Boitnott; J L Cameron
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

4.  Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases.

Authors:  J H Lewis; H L Tice; H J Zimmerman
Journal:  Dig Dis Sci       Date:  1983-08       Impact factor: 3.199

5.  Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome.

Authors:  H Bismuth; D J Sherlock
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

6.  Effect of portosystemic shunting on PGI2 and glucagon levels in humans.

Authors:  J V Sitzmann; K A Campbell; Y Wu; J L Cameron
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

7.  Current management of the Budd-Chiari syndrome.

Authors:  A S Klein; J V Sitzmann; J Coleman; F H Herlong; J L Cameron
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.